{{Drugbox
| IUPAC_name = 2-<nowiki/>{4-[(2''S'')-2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one
| image = Ciladopa.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 80109-27-9
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 133371
| ChEMBL = 2110793
| ChemSpiderID = 117659
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D09L486R3J

<!--Chemical data-->
| C=21 | H=26 | N=2 | O=4 
| molecular_weight = 370.44 g/mol
| smiles = O=C3/C=C\C=C/C=C3/N2CCN(C[C@@H](O)c1ccc(OC)c(OC)c1)CC2
}}

'''Ciladopa''' ('''AY-27,110''') is a [[dopamine agonist]] with a similar [[chemical structure]] to [[dopamine]].<ref name="pmid3927334">{{cite journal | author = Voith K | title = The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats | journal = Psychopharmacology | volume = 85 | issue = 4 | pages = 405–9 | year = 1985 | pmid = 3927334 | doi = 10.1007/BF00429654| url = }}</ref> It was under investigation as an [[antiparkinsonian agent]] but was discontinued due to concerns of [[tumorogenesis]] in rodents.<ref name="pmid3774130">{{cite journal |vauthors=Koller WC, Fields JZ, Gordon JH, Perlow MJ | title = Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug | journal = Neuropharmacology | volume = 25 | issue = 9 | pages = 973–9 |date=September 1986 | pmid = 3774130 | doi = 10.1016/0028-3908(86)90190-5| url = }}</ref><ref name="pmid3332914">{{cite journal |vauthors=Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J | title = A double-blind evaluation of ciladopa in Parkinson's disease | journal = Movement Disorders : Official Journal of the Movement Disorder Society | volume = 2 | issue = 3 | pages = 211–7 | year = 1987 | pmid = 3332914 | doi = 10.1002/mds.870020308 | url = }}</ref><ref name="pmid3574692">{{cite journal |vauthors=Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M | title = Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa | journal = Neurology | volume = 37 | issue = 5 | pages = 863–5 |date=May 1987 | pmid = 3574692 | doi = 10.1212/wnl.37.5.863| url = }}</ref><ref name="pmid3315148">{{cite journal | author = Lang AE | title = Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine" | journal = The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques | volume = 14 | issue = 3 Suppl | pages = 474–82 |date=August 1987 | pmid = 3315148 | doi = | url = }}</ref>

== References ==
{{Reflist}}

{{Antiparkinsonian}}
{{Dopaminergics}}
{{Phenethylamines}}

[[Category:Dopamine agonists]]
[[Category:Phenethylamines]]
[[Category:Piperazines]]
[[Category:Phenol ethers]]
[[Category:Tropones]]